BioMarin's resources did not go unnoticed by ... compared to Voxzogo's once-a-day doses. Meanwhile, Japanese pharma Otsuka recently picked up a clinical-stage PKU asset from Jnana Therapeutics ...

BioMarin Pharmaceutical Inc. (NASDAQ ... Outside of the U.S. and in our larger strategic markets, such as Germany and Japan, we will continue to focus on early diagnosis and treatment of the ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...

BioMarin's increasing profitability is also ... Outside of the U.S. and in our larger strategic markets, such as Germany and Japan, we will continue to focus on early diagnosis and treatment ...